Biotechnology
Kyoto University Engineering Ph.D. Team Realizes Achievement Transformation in Chengdu; LivingPhoenix's Biomimetic Collagen Rated "International Leading-Edge"
—— Globally Pioneering POGMENT Triple-Helix Biomimetic Collagen Debuts at Chinese Biomaterials Congress 2025 CHENGDU, China, Oct. 14, 2025 /PRNewswire/ -- The 2025 Chinese Biomaterials Congress was recently held in Shaoxing,Zhejiang, gathering leading experts including academicians from the Chin...
2025-10-14 17:22
1583
Great Novel Therapeutics Biotech & Medicals Corporation (GNTbm) Presented Preclinical Data on GNTbm-TKI, a Novel Multi-tyrosine Kinase Inhibitor with Potent Immune Activation, at the 2025 ESMO Annual Meeting
TAIPEI, Oct. 14, 2025 /PRNewswire/ -- GNTbm (stock code: 7427, Taiwan) announced the preclinical data on GNTbm-TKI, a novel multi-receptor tyrosine kinase inhibitor for cancer immunotherapy. GNTbm-TKI will be presented as posters at the 2025European Society for Medical Oncology (ESMO) Annual Meet...
2025-10-14 14:26
999
HKEX to Introduce Hang Seng Biotech Index Futures
* Hang Seng Biotech Index Futures to launch on 28 November 2025 * New futures contracts offer risk management tools for one of the fastest growing sectors inHong Kong capital markets * SFC Transaction Levy Exemption will be applied for the first six months from launch HONG KONG, Oct. 14, 202...
2025-10-14 12:43
1908
Everest Medicines Announces First Patient Enrolled in a Global Multi-Center Phase I Clinical Trial of Tumor-Associated Antigen Cancer Vaccine EVM14
SHANGHAI, Oct. 14, 2025 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced that the first patient has been enro...
2025-10-14 12:13
1342
NABR Comment on IUCN Determination
WASHINGTON, Oct. 14, 2025 /PRNewswire/ -- The International Union for
Conservation of Nature (IUCN) issued a decision onOctober 9, 2025, to retain
the "Endangered" status determination for long-tailed macaque ("LTM") monkeys (
Macaca fascicularis).
2025-10-14 06:55
1346
Natural Field Drives Breakthroughs in Co-loading Liposome Technology, Accelerating Upgrading of Raw Materials for Cardiovascular and Gut Health
XIAN, China, Oct. 13, 2025 /PRNewswire/ -- Natural Field has achieved new continuous research breakthroughs in co-loading liposome technology, with remarkable progress particularly in the development of co-loading Coenzyme Q10 (CoQ10) liposome and co-loading curcumin liposome raw materials. This ...
2025-10-13 23:00
1301
Visionary Holdings (Nasdaq: GV) Secures Global License for Breakthrough Stem Cell Technology Aimed at Diabetes Remission and Potential Complete Cure in a USD 150 Billion Global Market
TORONTO, Oct. 13, 2025 /PRNewswire/ -- Visionary Holdings Inc. ("GV" or the "Company"), a technology-driven multinational enterprise listed on Nasdaq (Nasdaq: GV), today announced that its wholly owned subsidiary,Visionary Holdings (Asia) Limited, has entered into a Global Product and Technology ...
2025-10-13 21:40
1686
iRegene Therapeutics announced promising NouvNeu001 Phase I clinical data
CHENGDU, China, Oct. 13, 2025 /PRNewswire/ -- iRegene Therapeutics Co., Ltd. ("iRegene" or the "Company") is recognized as a biotechnology company pioneering chemically induced allogeneic cell therapy. iRegene's lead product, NouvNeu001, is the 1st iPSC therapy to receive IND approval from both t...
2025-10-13 21:00
1093
NEXTBIOMEDICAL Announces First Patient Enrolled in U.S. FDA Pivotal Trial of Nexsphere-F™ for Knee Osteoarthritis Pain
* RESORB Study Marks Major Step Toward U.S. Regulatory Approval and Global Commercialization SEOUL, South Korea, Oct. 13, 2025 /PRNewswire/ -- NEXTBIOMEDICAL CO., LTD. (KOSDAQ: 389650), an innovative medical device company based inSouth Korea, today announced the enrollment of the first patient...
2025-10-13 21:00
1354
Complete Genomics announces Gene by Gene as its newest sequencing service provider at ASHG
BOSTON, Oct. 13, 2025 /PRNewswire/ -- Complete Genomics
2025-10-13 21:00
1259
ReviR Therapeutics Receives Orphan Drug Designation from FDA for RTX-117 to Treat Charcot-Marie-Tooth Disease
BRISBANE, Calif. , Oct. 13, 2025 /PRNewswire/ -- ReviR Therapeutics, a biotech company focused on developing novel treatments for neurogenetic diseases, announced today that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) for RTX-117, its lead investigational...
2025-10-13 18:00
1062
LTS expands its CDMO capabilities with the acquisition of Renaissance Lakewood
ANDERNACH, Germany, Oct. 13, 2025 /PRNewswire/ -- LTS LOHMANN Therapie-Systeme AG ("LTS"), a leading pharmaceutical technology company today announces the acquisition of Renaissance Lakewood, LLC ("Renaissance"), a US-based contract development and manufacturing organization (CDMO) specializing i...
2025-10-13 18:00
1244
AnnJi Showcases Clinical Breakthrough of AJ201 at WMS 2025
TAIPEI, Oct. 13, 2025 /PRNewswire/ -- AnnJi Pharmaceutical Co., Ltd. (AnnJi, TWSE: 7754) announced that the Phase 2a clinical result of AJ201 for spinal and bulbar muscular atrophy (SBMA, also known as Kennedy's disease) was selected as one of the seven Late-Breaking Abstracts at the World Muscle...
2025-10-13 16:03
1287
Lundbeck's bexicaserin receives Breakthrough Therapy Designation in China for the treatment of seizures in severe rare epilepsies
* Accelerated pathway underscores urgent need for innovative solutions for patients with devastating, childhood-onset epilepsies * Novel 5HT2C mechanism designed to reduce drug-resistant seizures in children and adults living with Developmental Epileptic Encephalopathies (DEEs) and improve qu...
2025-10-13 14:26
1119
GC Biopharma Secures CMO Rights for Shingles Vaccine from Curevo Vaccine
YONGIN, South Korea, Oct. 13, 2025 /PRNewswire/ -- GC Biopharma (006280.KS), a South Korean biopharmaceutical company, announced today that it has signed an agreement with Curevo Vaccine to secure contract manufacturing (CMO) rights for amezosvatein (development name: CRV-101), a recombinant shin...
2025-10-13 12:38
1818
Everest Medicines Announces NMPA Approval of IND Application for Tumor-Associated Antigen Cancer Vaccine EVM14
* EVM14 becomes Everest Medicines' internally developed therapeutic mRNA cancer vaccine to receive IND approvals from bothChina's National Medical Products Administration (NMPA) and the U.S. Food and Drug Administration (FDA). * EVM14, an off-the-shelf therapeutic mRNA cancer vaccine, is devel...
2025-10-13 08:47
1424
C-Ray Therapeutics (Chengdu) Co., Ltd Congratulates Partner Biokin Pharmaceutical on NMPA IND Approval of First Proprietary ARC Drug [177Lu]-BL-ARC001
CHENGDU, China, Oct. 11, 2025 /PRNewswire/ -- C-Ray Therapeutics (Chengdu) Co.,Ltd proudly congratulates its strategic partner,Biokin Pharmaceutical, on receiving implied approval from theNational Medical Products Administration (NMPA) for the clinical trial application of [177Lu]-BL-ARC001 Injec...
2025-10-11 20:45
2392
Roche Collaborates with OASES to Drive Primary Healthcare Transformation and Innovation, Strengthening Hong Kong's Position as a Global Healthcare Hub
HONG KONG, Oct. 10, 2025 /PRNewswire/ -- Roche announced its strategic collaboration with the Office for Attracting Strategic Enterprises (OASES) to accelerate healthcare innovation and strengthenHong Kong's role as a leading hub for life sciences and medical technology in theAsia Pacific region....
2025-10-10 21:11
2784
WuXi Biologics Receives MSCI AAA ESG Rating for Third Consecutive Year
SHANGHAI, Oct. 9, 2025 /PRNewswire/ -- WuXi Biologics (2269.HK), a leading global Contract Research, Development, and Manufacturing Organization (CRDMO), announced it has received the esteemed AAA ESG rating from Morgan Stanley Capital International (MSCI) for the third consecutive year. This to...
2025-10-10 08:30
1354
Celltrion receives U.S. FDA approval for EYDENZELT® (aflibercept-boav), biosimilar referencing EYLEA® (aflibercept)
* EYDENZELT® is approved for the treatment of patients with neovascular (wet) age-related macular degeneration (wAMD), macular edema following retinal vein occlusion (RVO), diabetic macular edema (DME), and diabetic retinopathy (DR) * Celltrion plans to enter the U.S. ophthalmology market to m...
2025-10-10 06:56
2344
Week's Top Stories
Most Reposted
Agoda Launches Free Global eSIMs for VIP Diamond Members
[Picked up by 322 media titles]
2026-02-10 14:00
Ascentium Acquires Clara, Expanding into the Abu Dhabi Global Market (ADGM) and Strengthening its Middle East Presence
[Picked up by 310 media titles]
2026-02-12 14:00
Rockwell Automation Strengthens Industrial Cybersecurity with New Security Operations Center in Singapore
[Picked up by 299 media titles]
2026-02-09 10:00
Blackpanda Japan Announces Strategic Partnership with SoftBank to Strengthen Cyber Incident Response in Japan
[Picked up by 299 media titles]
2026-02-10 13:31Carro unveils quirky generative AI ad campaign highlighting its 'Surprisingly Short' AI-enabled car-selling process
[Picked up by 296 media titles]
2026-02-11 11:00
Most Read
Angel Yeast Indonesia Project: Strengthening Foundations through Technical Training and Building Consensus through Cultural Exchange
2026-02-07 09:31
9528
NYSE Content Update: Children's Food Brand Once Upon a Farm to Open for Trade
2026-02-07 01:09
7544
Doorzo Ends 2025 with Its Strongest Year, Reaching a Decade Total of ¥80 Billion and Reinforcing Its Vision as "Your Gateway to Japan"
2026-02-07 07:00
6917
/C O R R E C T I O N -- Fairland Group - iGarden/
2026-02-08 17:31
6717
